Directorate Change

RNS Number : 7864G

Ovoca Bio PLC

26 July 2019

 

Ovoca Bio plc

("Ovoca" or the "Company")

Directorate Change

Ovoca Bio plc (LSE: OVB; ISE: OVXA) announces that Yuri Radchenko, a Non-Executive Director of the Company, has notified the board of his intention to step down with immediate effect due to personal circumstances.

Kirill Golovanov, CEO of Ovoca, commented: "On behalf of the Company, I would like to thank Yuri for his significant contribution to Ovoca over the years, from being instrumental in developing the mining interests of the Company when he first joined in 2006 through to his support in the acquisition of IVIX last year which commenced the next stage in Ovoca's journey. We wish him the very best for the future."

For further information: 

Ovoca Bio plc 

Kirill Golovanov (Chief Executive)

Tel [phone]

[e-mail]

Davy (Nominated Adviser, Euronext Growth Advisor and Broker)

John Frain / Daragh O'Reilly

Tel: [phone]

About Ovoca Bio plc

Ovoca Bio plc's goal is to become a leader in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. In 2018, Ovoca Bio acquired IVIX and its promising clinical stage asset, Libicore (BP-101), for female sexual dysfunction, an area of significant unmet medical need. The magnitude of demand for treatments for female sexual dysfunction has only recently been recognized, and Ovoca believes it has the potential to become a substantial pharmaceutical market.

About IVIX

IVIX, a Russian‐incorporated company, was formed in 2012 and since that time has sought to develop and subsequently commercialise a proprietary drug candidate, BP101 (known as "Libicore"), for the treatment of female sexual dysfunctions. Libicore is a novel synthetic peptide, administrated through a nasal spray. Clinical studies completed to-date have demonstrated statistically significant efficacy in the treatment of major forms of female sexual dysfunction. So far, IVIX has reached and completed Phase II clinical studies in Russia for Libicore. It now intends to complete the ongoing Phase III clinical trial for Libicore, following which it will seek approval for the marketing of Libicore in the Russian market, as well seek to expand its use internationally.

 

END

 

 

BOAUVABRKWABUAR